Mounjaro Coupons Discontinued, New Weight Loss Drug Zepbound

Mounjaro Coupon No Longer Available Under Original Brand Name

Mounjaro, a once-weekly injectable medication used for blood sugar control and weight loss in type 2 diabetes patients, will soon no longer be available under its original brand name. The FDA recently approved the medication to now be marketed exclusively for weight management under the new brand name Zepbound.

FDA Approval of Tirzepatide for Chronic Weight Management

In December 2022, the FDA approved tirzepatide, the active ingredient in Mounjaro, to be sold under the name Zepbound specifically for chronic weight management in adults. This followed positive results from late-stage clinical trials showing significant weight loss in those with obesity or who were overweight along with at least one weight-related health issue.

The trials demonstrated that more trial participants receiving tirzepatide lost at least 20% or at least 25% of their body weight compared to those receiving placebo. Participants also showed improvements in lipid profiles and blood pressure readings.

Gradual Transition from Mounjaro to New Brand Name Zepbound

The pharmaceutical company Eli Lilly, maker of both Mounjaro and the newly approved Zepbound, will gradually transition distribution from the Mounjaro brand to solely marketing the weight loss injection as Zepbound moving forward. This transition process will occur over 2023.

While Mounjaro coupons and savings cards will eventually be discontinued, the medication itself will still be available for obesity treatment under its new name Zepbound likely around late 2023. Patients currently using Mounjaro should begin transitioning to the Zepbound brand next year through their healthcare providers.

Mounjaro Savings Program and Coupons Phased Out

The Mounjaro Savings Card program allowed eligible patients with commercial insurance to pay as little as $25 per month for their once-weekly injection, a significant discount off typical pricing. Uninsured patients could also access the medication for $99 per month.

However, as production shifts from Mounjaro to solely Zepbound vials towards the end of 2023, the Mounjaro savings program and coupons will begin being phased out. Patients can no longer rely on the affordability previously offered through Mounjaro manufacturer discounts and copay assistance.

Zepbound Pricing and Access Solutions

While the excellent savings previously available to patients will change with the transition from Mounjaro to Zepbound, the manufacturer Eli Lilly states they are committed to making the new brand name medication affordable and accessible to appropriate patients needing it for chronic weight management.

Eli Lilly Launching New Zepbound Savings Program

Eli Lilly has said they will be establishing a new savings card program for Zepbound (tirzepatide) to help patients cover out-of-pocket costs just as theyve done with other brand medications. The details are still being finalized, but this will hopefully help offset some costs for patients previously dependent on Mounjaro copay coupons.

Additional Patient Assistance Options

Along with the pending Zepbound savings card program, Eli Lilly also offers several other patient support and assistance options that may provide financial relief for qualifying applicants who lack insurance coverage or meet certain income thresholds.

These options include the Lilly Cares Foundation for uninsured patients, the Lilly Patient One program for low- to medium-income families, and their Medicare Part D Patient Assistance Program for beneficiaries needing help affording medications.

Talk to Your Healthcare Provider About Alternatives

If Zepbound ends up still being unaffordable even with the new savings program and patient assistance options, talk to your provider. There may be more economical weight loss medications or off-label type 2 diabetes medicines that could be feasible stand-ins for those depending on tirzepatide treatment for blood sugar control and weight management.

The Future of Tirzepatide

While the Mounjaro savings program is set to eventually disappear, the medication itself will remain available for obesity and weight management under its new name Zepbound. Branded tirzepatide injections offer clinically validated effectiveness for weight loss and diabetes control.

The safety and efficacy should theoretically stay the same during the brand transition. Patients will simply need to get used to asking for prescriptions of Zepbound rather than Mounjaro vials when they become available over 2023.

Stay up to date on access and pricing details through Eli Lilly's Zepbound website once launched. Patients dependent on tirzepatide can also enroll in new savings programs as released and determine if other patient assistance options can offset costs as Mounjaro discounts get phased out.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.